EyePoint (EYPT) falls 1.29% for August 25
Today, EyePoint Pharmaceuticals Inc Inc’s (NASDAQ: EYPT) stock fell $0.13, accounting for a 1.29% decrease. EyePoint opened at $10.10 before trading between $10.15 and $9.91 throughout Wednesday’s session. The activity saw EyePoint’s market cap fall to $286,837,229 on 506,043 shares -above their 30-day average of 108,595.
About EyePoint Pharmaceuticals Inc
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint’s proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.
Visit EyePoint Pharmaceuticals Inc’s profile for more information.
About The Nasdaq Stock Market
The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world’s leading exchange for options volume and is home to the five largest US companies – Apple, Microsoft, Amazon, Alphabet and Facebook.
To get more information on EyePoint Pharmaceuticals Inc and to follow the company’s latest updates, you can visit the company’s profile page here: EyePoint Pharmaceuticals Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer
Warren Buffett-Backed Nubank To Seek $55 Billion IPO Valuation
Southern California Facing Same Wildfire Dangers That Have Scorched the North
Delta Air Lines To Charge Unvaccinated Employees $200 Per Month
Secretary of State Blinken Says 1,500 Americans May Still Be Awaiting Evacuation From Afghanistan
Salesforce Beats Fiscal Q2 Estimates; Raises Guidance for Q3
Most of Available Federal Rental Assistance Has Not Been Distributed: Treasury Department
Warby Parker Files for NYSE Direct Listing
Dr. Anthony Fauci Sees Pandemic Lasting Until at Least Spring 2022